The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

The FDA released last Friday newly updated label information for pioglitazone (Actos) and medications that contain Actos. The new labeling warns that use of Actos for more than a year may increase the risk of bladder cancer, a finding based on an interim analysis of an epidemiological study.

Other medications that will carry the warning include pioglitazone/metformin (Actoplus Met), pioglitazone/metformin extended release (Actoplus Met XR), and pioglitazone/glimepiride (Duetact).

The updated label recommends against use of pioglitazone in patients with active bladder cancer and urges cautious use in those with a history of bladder cancer.

It also urges patients to contact their healthcare provider if they experience any potential symptoms of bladder cancer, including blood in their urine, urinary urgency, or pain on urination.

The original warning on pioglitazone was based on an interim review of an ongoing epidemiological study of almost 200,000 diabetic patients by drugmaker Takeda, and came just days after France and Germany banned the use of the drug.

One Comment

  1. Gravatar for Daniel Haszard

    Eli Lilly Zyprexa can *cause* diabetes.

    I took Zyprexa a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.

    Eli Lilly's #1 cash cow Zyprexa drug sale $40 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.

    -- Daniel Haszard

Comments are closed.

Of Interest